1st DIA India’s Cardiac safety Conference

Cardiovascular toxicity and adverse eff ects are the leading reasons why
pharmaceuticals are stopped during development and why approved
pharmaceuticals are withdrawn from the market. Several high profi le
withdrawals in recent years have triggered public concerns and heightened
regulatory focus and scrutiny on cardiac safety of pharmaceuticals
under development—making cardiac safety a top priority for pharmaceutical
companies. This meeting will discuss guidelines and best practices
for both QT and non-QT-related cardiac safety issues, including the
IC4-E-14 Guidance and the FDA Guidance on Evaluating Cardiovascular
Risk for New Anti-diabetic Drugs.